Aprea Therapeutics, Inc. (APRE) Key Metrics
APRE valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $7.4M
- Enterprise value
- −$31.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- — 10-yr median 19.5
- Price / book
- 0.3 10-yr median 0.9
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 1.63
APRE key metrics, 2013–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAPRE valuation Price multiples at each fiscal year-end price.
Price / sales+61.8%
19.5
2025 · hover or tap a bar for each year
20132025
Price / book−52.3%
0.4
2025 · hover or tap a bar for each year
20132025
Free cash flow yield−156.3 pts
−231.2%
2025 · hover or tap a bar for each year
20132025
APRE returns How much profit the business earns on the capital it uses.
Return on equity−10.4 pts
−79.4%
2025 · hover or tap a bar for each year
20132025
Return on assets−7.6 pts
−63.1%
2025 · hover or tap a bar for each year
20132025
Asset turnover−77.8%
0.01
2025 · hover or tap a bar for each year
20132025
APRE per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−84.0%
$0.04
2025 · hover or tap a bar for each year
20132025
Earnings per share
−$1.93
2025 · hover or tap a bar for each year
20132025
Free cash flow per share
−$1.97
2025 · hover or tap a bar for each year
20132025
Book value per share−45.7%
$1.90
2025 · hover or tap a bar for each year
20132025
Shares outstanding+18.7%
6.5M
2025 · hover or tap a bar for each year
20132025
APRE financial health Debt, liquidity and how easily interest is covered.
Net debt+$8.3M
−$14.6M
2025 · hover or tap a bar for each year
20132025
Current ratio−19.8%
5.63
2025 · hover or tap a bar for each year
20132025
APRE efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding+17,304 days
17,363 days
2025 · hover or tap a bar for each year
20132025
Capex / revenue−1.0 pts
0.0%
2025 · hover or tap a bar for each year
20132025
APRE valuation history
Fiscal year-endToday10-year median
APRE returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
APRE debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
APRE price vs earnings per share
Share price at year-endEPS (right axis)
APRE key metrics
2013–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $5.6M | $18.1M | $17.0M | — | — | — | — | — | — | — |
| Enterprise value | −$9.0M | −$4.7M | −$4.6M | — | — | — | — | — | — | — |
| Price / sales | 19.5 | 12.1 | 29.2 | — | — | — | — | — | — | — |
| Price / book | 0.4 | 0.9 | 0.9 | — | — | — | — | — | — | — |
| EV / sales | -31.6 | -3.1 | -7.9 | — | — | — | — | — | — | — |
| Earnings yield | −225.9% | −71.5% | −84.0% | — | — | — | — | — | — | — |
| Free cash flow yield | −231.2% | −74.9% | −72.2% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $0.85 | $3.29 | $4.70 | $6.62 | $57.40 | $98.40 | $917.80 | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.04 | $0.27 | $0.16 | — | — | — | — | — | — | — |
| Earnings per share | −$1.93 | −$2.35 | −$3.95 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$1.97 | −$2.46 | −$3.37 | — | — | — | — | — | — | — |
| Free cash flow per share | −$1.97 | −$2.46 | −$3.39 | — | — | — | — | — | — | — |
| Cash per share | $2.23 | $4.15 | $5.97 | — | — | — | — | — | — | — |
| Book value per share | $1.90 | $3.50 | $5.05 | — | — | — | — | — | — | — |
| Tangible book value per share | $1.90 | $3.50 | $5.05 | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.03 | — | — | — | — | — | — | — |
| Shares outstanding | 6.5M | 5.5M | 3.6M | — | — | — | — | — | — | — |
| Change in shares outstanding | +18.7% | +52.3% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −79.4% | −69.0% | −65.1% | −299.8% | −57.6% | −53.5% | −77.1% | — | — | — |
| Return on assets (ROA) | −63.1% | −55.6% | −54.1% | −259.1% | −48.8% | −47.6% | −28.1% | −34.2% | −61.3% | — |
| Return on tangible assets | −79.1% | −54.0% | −63.1% | −373.6% | −64.3% | −58.1% | −21.0% | −23.5% | −61.3% | — |
| Free cash flow margin | — | −903.3% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | — | — | — | $190,471 | $335,156 | $544,950 | $0 | $0 | $1.5M |
| Cash & short-term investments | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M | $89.0M | $130.1M | $65.7M | $24.4M | — |
| Net debt | −$14.6M | −$22.8M | −$21.6M | −$28.8M | −$52.9M | −$88.7M | −$129.5M | −$65.7M | −$24.4M | $1.5M |
| Debt / equity | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
| Debt / assets | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current ratio | 5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | 5.75 | — |
| Quick ratio | 5.63 | 7.01 | 5.14 | 9.42 | 7.73 | 6.03 | 14.68 | 13.56 | 5.75 | — |
| Interest coverage | — | — | — | -252.7 | — | -237.2 | -189.0 | — | — | — |
| Working capital | $12.8M | $20.2M | $18.1M | $27.0M | $49.3M | $77.1M | $124.0M | $61.1M | $20.4M | — |
| Invested capital | −$2.2M | −$3.5M | −$3.3M | −$3.1M | −$3.4M | −$11.3M | −$5.3M | −$117.1M | −$60.2M | — |
| Tangible asset value | $12.4M | $19.3M | $18.3M | $25.6M | $49.5M | $77.4M | $124.2M | −$51.4M | −$35.8M | — |
| Net current asset value | $12.1M | $18.9M | $18.1M | $25.6M | $49.3M | $77.0M | $123.7M | −$51.5M | −$35.8M | — |
| Graham net-net per share | $1.70 | $3.30 | $4.76 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | — |
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | $0 | — |
| Capex / revenue | 0.0% | 1.0% | 16.0% | — | — | — | — | — | — | — |
| Capex / depreciation | 0.00 | 0.69 | 13.20 | 0.00 | 0.00 | 0.11 | 0.18 | 0.45 | 0.47 | — |
| Stock-based compensation / revenue | 167.3% | 32.6% | 76.2% | — | — | — | — | — | — | — |
| R&D / revenue | 2,464.7% | 623.2% | 1,307.8% | — | — | — | — | — | — | — |
| SG&A / revenue | 2,266.4% | 429.8% | 1,446.2% | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days payables outstanding | 17,362.6 | 58.9 | 65,037.6 | 29.1 | 4,216.4 | 5,309.8 | 4,197.9 | 74,640.4 | 135,268.8 | — |
| Payables turnover | 0.02 | 6.20 | 0.01 | 12.54 | 0.09 | 0.07 | 0.09 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.01 | 0.06 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Average payables | $1.0M | $1.5M | $1.3M | $1.3M | $3.1M | $3.3M | $2.0M | $1.7M | $2.9M | $4.0M |
| Average inventory | — | — | — | — | — | — | — | $0 | $0 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
Computed from APRE's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
APRE valuation and financial ratios
Aprea Therapeutics earned a return on equity of −79.4% in fiscal 2025.
See the APRE income statement, the APRE chart for price history, or the APRE stock overview for the latest quote and news.
APRE key metrics FAQ
What is Aprea Therapeutics's return on equity?
Aprea Therapeutics's return on equity (ROE) was −79.4% in fiscal 2025: net income of -$12.6 million on average shareholders' equity of $15.9 million.
What is Aprea Therapeutics's free cash flow yield?
Aprea Therapeutics generated -$12.9 million of free cash flow in fiscal 2025, a free cash flow yield of −231.2% on its market value at year-end ($5.6 million).
What is Aprea Therapeutics's current ratio?
Aprea Therapeutics's current ratio was 5.63 at the end of fiscal 2025: current assets were 5.63 times current liabilities.